Censavudine

Drug Profile

Censavudine

Alternative Names: 4'-Ethynyl-d4T - Oncolys BioPharma; 4'-ethynylstavudine; BMS-986001; Ed4T; Festinavir; OBP-601

Latest Information Update: 14 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Kagoshima University; Yale University
  • Developer Bristol-Myers Squibb
  • Class Antivirals; Furans; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - HIV-1 infections

Highest Development Phases

  • Phase II HIV-1 infections

Most Recent Events

  • 14 Aug 2017 Censavudine is still at phase II development stage for HIV-1 infections in countries worldwide (PO) (Oncolys BioPharma pipeline, August 2017)
  • 29 Jun 2017 Oncolys BioPharma completes a phase II trial in HIV infection in USA
  • 31 May 2016 Censavudine is available for licensing as of 30 Apr 2014. http://www.oncolys.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top